References
Horner ME, Alikhan A, Tintle S, Tortorelli S, Davis DMR, Hand JL. Cutaneous porphyrias part I: epidemiology, pathogenesis, presentation, diagnosis, and histopahhology. Int J Dermatol 2013; 52: 1464–80.
Christiansen AL, Brock A, Bygum A, Rasmussen LM, Jepsen P. Increased mortality in patients with porphyria cutanea tarda: a nationwide cohort study. J Am Acad Dermatol 2020; 83:817–23.
Frew JW, Marzano AV, Wolk K, et al. A systematic review of promising therapeutic targets in hidradenitis suppurativa: a critical evaluation of mechanistic and clinical relevance. J Invest Dermatol 2020; S0022–202X(20): 31826–31.
Savage KT, Flood KS, Porter ML, Kimball AB. TNF-α inhibitors in the treatment of hidradenitis suppurativa. Ther Adv Chronic Dis 2019; 10:2040622319851640.
Tzanetakou V, Kanni T, Giatrakou S, et al. Safety and efficacy of anakinra in severe hidradenitis suppurativa: a randomized clinical trial. JAMA Dermatol 2016; 152: 52–9.
Kanni T, Argyropoulou M, Spyridopoulos T, et al. MABp1 targeting IL-1α for moderate to severe hidradenitis suppurativa not eligible for adalimumab: a randomized study. J Invest Dermatol 2018; 138: 795–801.
Casseres RG, Prussick L, Zancanaro P, et al. Secukinumab in the treatment of moderate to severe hidradenitis suppurativa: results of an open-label trial. J Am Acad Dermatol 2020; 82: 1524–6.
Gulliver WP, Jemec GBE, Baker KA. Experience with ustekinumab for the treatment of moderate to severe hidradenitis suppurativa. J Eur Acad Dermatol Venereol 2012; 26:911–4.
Berman HS, Villa NM, Shi VY, Hsiao JL. Guselkumab in the treatment of concomitant hidradenitis suppurativa, psoriasis, and Crohn’s disease. J Dermatol Treat 2019: 1–3.
Patel N, McKenzie SA, Harview CL, et al. Isotretinoin in the treatment of hidradenitis suppurativa: a retrospective study. J Dermatol Treat 2019: 1–3.
Giamarellos-Bourboulis EJ, Argyropoulou M, Kanni T, et al. Clinical efficacy of complement C5a inhibition by IFX-1 in hidradenitis suppurativa: an open-label single-arm trial in patients not eligible for adalimumab. Br J Dermatol 2020; 183: 176–8.
Golbari NM, Porter ML, Kimball AB. Antiandrogen therapy with spironolactone for the treatment of hidradenitis suppurativa. J Am Acad Dermatol 2019; 80: 114–9.
Verdolini R, Clayton N, Smith A, Alwash N, Mannello B. Metformin for the treatment of hidradenitis suppurativa: a little help along the way. J Eur Acad Dermatol Venereol 2013; 27: 1101–8.
Savage KT, Santillan MR, Flood KS, Charrow A, Porter ML, Kimball AB. Tofacitinib shows benefit in conjunction with other therapies in recalcitrant hidradenitis suppurativa patients. JAAD Case Rep 2020;6:99–102.
Elman SA, Joyce C, Braudis K, et al. Creation and validation of classification criteria for discoid lupus erythematosus. JAMA Dermatol 2020; 156:901–6.
Fabbri P, Cardinali C, Giomi B, Caproni M. Cutaneous lupus erythematosus: diagnosis and management. Am J Clin Dermatol 2003;4:449–65.
Author information
Authors and Affiliations
Corresponding author
Additional information
Disclosure
Financial support: none. Conflicts of interest: none.
About this article
Cite this article
Lesort, C., Grän, F., Machado, Á. et al. Journal Club. Eur J Dermatol 30, 759–760 (2020). https://doi.org/10.1684/ejd.2020.3932
Published:
Issue Date:
DOI: https://doi.org/10.1684/ejd.2020.3932